Video

Q&A With Anne Cross from Washington University School of Medicine: Additional Treatments Could Provide Benefit to Patients With Multiple Sclerosis

Author(s):

The development of new monoclonal antibodies could provide benefit for patients with multiple sclerosis in the future. Exactly how they will be used and what their usage could mean for treatment remains to be determined.

The development of new monoclonal antibodies could provide benefit for patients with multiple sclerosis in the future. Exactly how they will be used and what their usage could mean for treatment remains to be determined.

Anne H. Cross from the Washington University School of Medicine discussed this potential new treatment during the 2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers in Indianapolis. Cross said that while these treatments have not been approved for patients with the relapsing form of the condition. She also added that if they are approved it will be important that only properly trained healthcare professionals provide them to patients.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.